1 active not recruiting, 1 not yet recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Not yet recruiting 1 |
Follow Longbio Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines LP-003 Injection, Omalizumab - Chronic Spontaneous Urticaria (CSU) | Phase 3 | Not yet recruiting | Longbio Pharma | 514 | 2026-12-07 | 2026-11-18 |
| Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis LP-003, Placebo - Seasonal Allergic Rhinitis | Phase 3 | Active not recruiting | Longbio Pharma | 546 | 2024-08-01 | 2025-12-26 |
Chronic Urticaria (1) · Rhinitis, Allergic, Seasonal (1)
Omalizumab (1)
China (2)
Xinghua Gao (1) · Xueyan Wang (1)